Medical Oncologist
CION Cancer Clinics
When is targeted therapy added for colon cancer? | CION Cancer Clinics
Targeted therapy is added to chemotherapy mainly when colon cancer has spread or come back. It is not part of standard treatment after surgery for stage 1 to 3 disease, because trials found it did not help there. Which drug is chosen depends on tests on the tumour itself. This page explains when a targeted drug is added, which one, and who it does not suit. At CION Cancer Clinics, a multidisciplinary team plans colon cancer treatment for your stage, from surgery to chemotherapy and follow-up.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- When is targeted therapy used for colon cancer?
- Which targeted drug is used for which tumour?
- What has to happen before a targeted drug is started?
- What do the words on a molecular report mean?
- What do families often get wrong about targeted therapy?
- What this page cannot tell you
- Common questions about targeted therapy in colon cancer
The short answer
When is targeted therapy used for colon cancer?
Targeted therapy is used mainly when colon cancer has spread beyond the colon, usually to the liver, lungs or the lining of the abdomen, or when it has come back after treatment. In that setting a targeted drug is usually added to chemotherapy, not given in place of it. It is rarely part of treatment for a cancer that surgery has fully removed.
Why it is not added after surgery for stage 1 to 3
After a successful operation for stage 2 or 3 colon cancer, chemotherapy is given to clear any cells that may have been left behind. Large trials added bevacizumab or cetuximab to that chemotherapy and found it did not lower the chance of the cancer coming back. So adjuvant treatment, meaning treatment given after surgery, is chemotherapy alone. If a targeted drug is suggested at this stage, ask why.
What decides whether it is added at all
Three things: tests on the tumour, the side of the colon where it started, and how fit you are. The tests show whether a drug has a target to hit. The side shows which drug family is likely to work better. Your fitness decides whether you can manage a combination, or would do better on something gentler. The tumour board weighs all three before anything is added.
Targeted therapy is not a stronger chemotherapy. It works differently, and it works only when the tumour carries what the drug is aimed at.The drug families
Which targeted drug is used for which tumour?
Colon cancer has a handful of targets that matter. Each drug family needs a particular test result before it is worth giving.
Drugs that cut the blood supply
Bevacizumab blocks a signal tumours use to grow new blood vessels. It does not depend on a gene result, so it can be used whatever the RAS test shows. It is often paired with FOLFOX, CAPOX or FOLFIRI in first-line treatment.
Usually held back when
- An operation is planned soon
- There has been a recent serious bleed
- Blood pressure is not controlled
Drugs that block the EGFR switch
Cetuximab and panitumumab block a growth signal on the surface of the cancer cell. They help only when the RAS genes are normal, which reports call RAS wild-type, and they work best in left-sided tumours. If KRAS or NRAS is altered, they are not given.
Drugs for a BRAF change
A small group of colon cancers carry a change called BRAF V600E. These tend to grow faster and respond less well to standard chemotherapy alone. For them, a BRAF-blocking tablet is combined with cetuximab, either after first-line treatment or, increasingly, from the start alongside chemotherapy.
HER2 and rarer targets
A few tumours carry extra copies of HER2, a change better known from breast cancer. Fewer still carry a KRAS G12C change or an NTRK gene fusion. Each has its own drug, usually used after standard treatment. These rarer targets are tested for when the result would change the plan.
Not sure whether this applies to you?
Ask an oncologistBefore a drug is added
What has to happen before a targeted drug is started?
The tumour is tested
A sample from the colonoscopy biopsy or the operation is tested for RAS, BRAF, MSI and often HER2. CION arranges this through its diagnostic partners. Waiting for these results is worth it, because the wrong drug can do nothing at all.
MSI-high is checked first
If the tumour is MSI-high, meaning its DNA repair system is faulty, immunotherapy usually comes before any targeted drug. That result changes the whole first plan.
The board chooses the pairing
A targeted drug is paired with a chemotherapy regimen. The tumour board chooses the pairing from the test results, the side of the tumour, and whether the aim is to shrink liver spots enough for an operation.
Scans set a starting point
A CT scan before the first cycle gives a baseline. Repeat scans every few cycles show whether the combination is working, and the plan changes if it is not.
On your report
What do the words on a molecular report mean?
- RAS wild-type
- Neither KRAS nor NRAS is altered. This is the result that makes an EGFR-blocking drug an option.
- RAS mutant
- KRAS or NRAS is altered. EGFR-blocking drugs will not help, and bevacizumab is the usual partner for chemotherapy.
- BRAF V600E
- A specific change in the BRAF gene. It points to a faster-growing cancer that has its own drug combination.
- MSI-high or dMMR
- The tumour's DNA repair system is faulty. Immunotherapy is often the first choice for these tumours.
- HER2-amplified
- The tumour carries too many copies of HER2. This is rare in colon cancer and is treated with HER2-blocking drugs.
- First-line
- The first treatment used for advanced disease. Second-line is what follows if the first stops working.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often get wrong about targeted therapy?
"Targeted therapy is newer, so it must be better than chemotherapy."
In colon cancer, targeted drugs are almost always added to chemotherapy rather than replacing it. On their own, most of them do far less. They add something only when the tumour carries the right target.
"Adding it after surgery will stop the cancer coming back."
Trials tested exactly this for stage 2 and 3 colon cancer and found no benefit. After surgery, chemotherapy alone is the standard. A targeted drug at that stage adds cost and side effects without the gain.
"If one targeted drug is good, two together must be better."
Giving bevacizumab and an EGFR-blocking drug together was tested, and people did worse. The team chooses one drug family at a time, based on the test results.
"If I do not qualify for a targeted drug, treatment is pointless."
Many people with a RAS change or a right-sided tumour are treated well with chemotherapy and bevacizumab, or with chemotherapy alone. Not qualifying for one drug is not the same as running out of options.
Being straight with you
What this page cannot tell you
It cannot tell you whether a targeted drug suits you. That depends on your own tumour results, scans and general health, read together by the team treating you. Two people with the same stage can be offered quite different plans, and both can be right.
Who this does not apply to
If your colon cancer has been fully removed and was stage 1, 2 or 3, targeted therapy is not part of standard treatment for you. If your tumour is MSI-high, immunotherapy is usually considered first. If the cancer is in the rectum, some decisions differ, and the rectal cancer pages are the right place to start.
It cannot answer the cost question for you
Targeted drugs are costly, and biosimilar versions have changed the prices. Insurance policies and government schemes treat them differently. The targeted therapy cost page linked below explains what moves the bill. CION gives targeted therapy at its centres and can give you a written estimate before the first cycle.
If you are holding a molecular report and are unsure what it means for treatment, bring it to a consultation. A medical oncologist can read it through with you.Questions we are asked
Common questions about targeted therapy in colon cancer
Is targeted therapy used for stage 3 colon cancer?
Not as standard. After surgery for stage 3, chemotherapy alone is given, because trials adding bevacizumab or cetuximab showed no benefit. Targeted therapy becomes relevant if the cancer had already spread when it was found, or if it spreads or comes back later.
Can targeted therapy be given without chemotherapy?
Sometimes, but rarely as the first treatment. In later lines, some targeted drugs are taken as tablets on their own, and some combinations for rarer changes leave out standard chemotherapy. For most people, the targeted drug is given alongside chemotherapy.
How long is targeted therapy continued?
Usually for as long as it keeps the cancer controlled and the side effects stay manageable. After an initial period, some people step down to lighter maintenance treatment, often keeping bevacizumab with a single chemotherapy drug. Planned breaks are sometimes possible too.
Why was I offered bevacizumab and not cetuximab?
Usually because the tumour has a RAS change, which rules cetuximab out, or because it started on the right side of the colon, where cetuximab works less well. Bevacizumab does not depend on the RAS result. Ask your oncologist which of these applied to you.
Can targeted therapy shrink liver spots enough for surgery?
Sometimes. When liver metastases cannot be removed at first, chemotherapy with a targeted drug can shrink them until an operation becomes possible. Only some people reach that point, and the tumour board decides. The operation is done at an accredited partner hospital.
Does a KRAS change mean no targeted therapy at all?
No. It rules out EGFR-blocking drugs, but bevacizumab still works alongside chemotherapy. If the change is the specific type called KRAS G12C, newer drugs aimed at it may be considered after earlier treatment has been tried.
Is targeted therapy given at CION?
Yes. Targeted therapy, chemotherapy and immunotherapy are given at CION centres, with monitoring between cycles. Tumour testing, scans and any surgery are arranged through accredited partners, and the tumour board reviews the results before a plan is confirmed.
What should I ask before a targeted drug is added?
Ask which test result made you eligible, what the drug is expected to add, which side effects to watch for, and what each cycle will cost. Ask what happens if it stops working. Call the CION helpline if you would like a second opinion on the plan.
Your Specialists
Meet CION's colon cancer specialists. Bring your colonoscopy, scan or biopsy report.
Our surgical and medical oncologists plan colon cancer care together: which operation, whether chemotherapy is needed, and the follow-up that comes after.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Colorectal Cancer Targeted Therapy
- American Cancer Society — Colon Cancer Treatment, by Stage
- National Cancer Institute — Colon Cancer Treatment
- National Cancer Institute — Targeted Therapy for Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Why tumour side changes the drug choiceWhy left and right tumours get different drugsWhy RAS and BRAF testing comes before treatmentThe tests that decide which drug is possibleWhen immunotherapy is an optionThe first choice when the tumour is MSI-highCost of targeted therapy in colon cancerWhat a targeted drug adds to the bill
Talk to us
Has a targeted drug been suggested, and you are unsure why?
Bring your scans and molecular report, and a CION medical oncologist will explain what the results mean for your treatment. One helpline serves every CION centre.